**Name of journal: World Journal of Psychiatry**

**ESPS Manuscript NO: 12823**

**Columns: Clinical Trials Study**

**Light treatment for seasonal winter depression in African American *vs* Caucasian outpatients**

Uzoma HN *et al*. Light for seasonal winter depression in African Americans

Hyacinth N Uzoma, Gloria M Reeves, Patricia Langenberg, Baharak Khabazghazvini, Theodora G Balis, Mary A Johnson, Aamar Sleemi, Debra A Scrandis, Sarah A Zimmerman, Dipika Vaswani, Gagan Virk Nijjar, Johanna Cabassa, Manana Lapidus, Kelly J Rohan, Teodor T Postolache

**Hyacinth N Uzoma, Gloria M Reeves, Baharak Khabazghazvini, Theodora G Balis, Aamar Sleemi, Dipika Vaswani, Sarah A Zimmerman, Gagan Virk Nijjar, Manana Lapidus,** **Teodor T Postolache,** Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201-1549, United States

**Hyacinth N Uzoma, Aamar Sleemi, Gagan Virk Nijjar,** Psychiatry Residency Training Program, St. Elizabeth's Hospital, Washington, DC 20032, United States

**Patricia Langenberg,** Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD 21201-1549, United States

**Mary A Johnson,** Department of Ophthalmology and Visual Science, University of Maryland School of Medicine, Baltimore, MD 21201-1549, United States

**Debra A Scrandis,** Family and Community Health, University of Maryland School of Nursing, Baltimore, MD 21201-1549, United States

**Kelly J Rohan,** Department of Psychological Science, University of Vermont, Burlington, VT 05405-0134, United States

**Author contributions:** Postolache TT, Rohan KJ, Johnson MA and Reeves GM conceptualized and designed the study; Uzoma HN, Rohan KJ, Scrandis DA and Postolache TT drafted the article, reviewed the literature and critically revised it for intellectual content; and all authors provided feedback on the manuscript. Balis TG, Khabazghazvini B, Sleemi A, Nijjar GV, Lapidus M, Zimmerman SA, Cabassa J and Vaswani D were responsible for research and data collection; Balis TG and Reeves GM supervised and monitored all study participants for any emergent condition; Johnson MA played a critical role in measurement of light administration as well as eye safety protocol; Langenberg P and Postolache TT performed the statistical analysis of the data. Postolache TT and Reeves G obtained financial support via NIH grants.

**Supported by** the NIH grant with Teodor Postolache as Principal Investigator, No. 1R34MH073797-01A2; NIH grant with Gloria Reeves as Principal Investigator, No. K12RR023250-01; and the General Clinical Research Centers Program, National Center for Research Resources of the National Institute of Health, No. M01 RR 16500

**Correspondence to: Teodor T Postolache, MD, Professor, Director,** Department of Psychiatry, University of Maryland School of Medicine, 685 West Baltimore Street, Suite 930, Baltimore, MD 21201-1549, United States. [tpostola@psych.umaryland.edu](mailto:tpostola@psych.umaryland.edu)

**Telephone:** +1-410-7062323 **Fax:** +1-410-7060751

**Received:** July 27, 2014 **Revised:** September 7, 2014

**Accepted:** November 17, 2014

**Published online:**

**Abstract**

**AIM:** To compare adherence, response, and remission with light treatment in African American and Caucasian patients with Seasonal Affective Disorder.

**METHODS:** 78 study participants, age range 18-64 (51 African Americans and 27 Caucasians) recruited from the Greater Baltimore Metropolitan area, with diagnoses of recurrent mood disorder with seasonal pattern, and confirmed by a Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV, were enrolled in an open label study of daily bright light treatment. The trial lasted 6 wk with flexible dosing of light starting with 10000 lux achromatic light for 60 min daily in the morning. Outcome measures were remission (score ≤ 8) and response (50% reduction) in symptoms on the Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-SAD) as well as symptomatic improvement on SIGH-SAD and Beck Depression Inventory-II. Adherence was measured using participant daily log. Participant groups were compared using t-tests, chi square, linear and logistic regressions.

**RESULTS:** 78 patients who met the study exclusion and inclusion criteria were enrolled, and at the end of six weeks there were 65 completers. Three patients had Bipolar II disorder and the remainder had Major depressive disorder. The age range was 18-64. The demographics showed African Americans *n* = 51, mean age 43.1, SD = 10.3; Caucasians *n* = 27, mean age 47.0, SD = 10.1. The study did not find any significant group difference between African Americans and their Caucasian counterparts in mood responses to light therapy or adherence with treatment as well as in symptomatic improvement. When adjusted for age, gender, and adherence, Caucasians demonstrated a significantly greater mean decrease than African-Americans on the Structured Interview Guide for Hamilton-Seasonal Affective Disorder subscale remission scores (African Americans 46.3%; Caucasians 75%; *P* = 0.02). No gender differences were observed in response or adherence with treatment.

**CONCLUSION:** Similar adherence, response and symptomatic improvement in this study suggest the need to increase awareness of this treatment modality in the group with lower remission rate.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Seasonal affective disorder; Depression; Light treatment; African Americans; Caucasians

**Core tip:** Consistent findings suggesting that light treatment is safe and effective for Seasonal affective disorder (SAD) emerged from prior research on samples with highly predominant Caucasian representation. As there are no previous reports on light treatment for SAD in African Americans, we undertook the first study comparing effects of light treatment in African American and Caucasian patients with Seasonal Affective Disorder. After six weeks of treatment, improvement in depression scores, response (50% improvement in symptoms), and adherence to treatment were similar between the two racial groups. However, the remission rates were significantly lower in African Americans. Thus additional research is needed to better understand and ultimately reduce the remission gap between Caucasian and African American patients with SAD.

Uzoma HN, Reeves GM, Langenberg P, Khabazghazvini B, Balis TG, Johnson MA, Sleemi A, Scrandis DA, Zimmerman SA, Vaswani D, Nijjar GV, Cabassa J, Lapidus M, Rohan KJ, Postolache TT. Light treatment for seasonal winter depression in African American *vs* Caucasian outpatients. *World J Psychiatr* 2014, In press

**INTRODUCTION**

Many species manifest behavioral and physiological changes in response to seasonal changes in day length. Today, the effect of day length on humans may be less than in other animals because artificial lighting may blunt macro-environmental photoperiodicity. However, a sizable proportion of individuals manifest more pronounced seasonal changes, with some having major depression episodes in the fall and winter with spontaneous remission in spring and summer, defined as Seasonal Affective Disorder with winter pattern (SAD)[1]. Symptoms of SAD resemble seasonal changes in physiology and behavior in other photoperiodic mammals (including changes in appetite, weight, sleeping patterns, and patterns of social interactions). Light treatment is a safe and efficacious antidepressant intervention for SAD[1-4]. It may also prove to be a beneficial treatment for non-seasonal depression[4,5], as the mechanisms underlying the antidepressant action of bright light treatment overlap in part with those of antidepressant medications[6,7]. Although it appears that the prevalence of SAD in African Americans is similar to the general population living at the same latitude[8], no previous study has focused on light treatment in African Americans. Based on previously reported lower rates of adherence to antidepressants in African American patients with non-seasonal depression[9,10], we hypothesized a lower adherence to light treatment, and a lower treatment response and remission in African American patients when compared to Caucasian patients with Seasonal Affective Disorder with winter pattern.

**MATERIALS AND METHODS**

This was a six-week study primarily focused on prediction of remission and response following light treatment in African-American and Caucasian patients with Seasonal Affective disorder with Winter pattern. It was conducted at the Mood and Anxiety Program of the University Of Maryland School Of Medicine in Baltimore. This study was an exploratory aim of an NIH- supported study (1R34MH073797-01A2). Recruitment took place over three consecutive Fall to Winter intervals, beginning in Fall 2007 and ending in winter 2010. Approval for the study protocol was obtained from the Institutional Review Board of the University of Maryland.

***Participants***

Participants in this study were patients with Seasonal Affective Disorder with winter pattern, recruited from the larger Baltimore metropolitan area through posters, flyers, and local newspaper ads. Figure 1 is a flow chart showing number of patients involved in the entire study from the initial telephone screening to the end. Patients self-identified as African Americans or Caucasians consistent with the methodology recommended by the National Research Council consensus document on race and ethnicity[11].

***Seasonal pattern assessment questionnaire***

Prescreening (screen #1) was conducted by phone using the Seasonal Pattern Assessment Questionnaire (SPAQ)[12]. This seventeen item psychometric instrument first designed by Rosenthal and colleagues has been widely used as a research instrument in the study of Seasonal Affective Disorder. It has been shown to be an accurate screening instrument for identifying patients with Seasonal Affective Disorder[13,14]. In one study by Magnusson, the SPAQ was shown to have sensitivity, specificity and positive predictive value for that group of 94%, 73% and 45%, respectively[15]. In another study, Young MA *et al*[16] reported that the SPAQ has good psychometric properties in terms of score distribution, test-retest reliability, internal consistency, factor structure and item-latent traits relationships. Several other studies have shown high sensitivity but low specificity for the SPAQ, thus making it a good screening but poor diagnostic tool. In our study, participants who received a SPAQ global seasonality score of 11 or greater, reported a winter pattern, as well as reported being at least moderately affected in daily functioning were considered positive screen. These individuals were invited to attend an in-person screening, informed consent session and for evaluation of eligibility to participate in the study.

In-person screening (screen #2) was performed by trained clinicians completing the Structured Clinical Interview for DSM-IV Axis I Disorders – Clinician Version (SCID-Clinician Version)[17].

***Inclusion and exclusion criteria***

Inclusion criteria for the study were: age 18–64; history of Major Depressive Disorder or Bipolar II Disorder with seasonal pattern specifier, by Diagnostic and Statistical Manual of mental disorders-IV, text revision (DSM-IV-TR) and/or a score of 21 or greater on the Structured Interview Guide for Hamilton Rating Scale for Depression-Seasonal Affective Disorder Version (SIGH-SAD)[18]. Eligible participants repeated the SIGH-SAD by phone interview 24 h prior to the first scheduled light session (screen #3), as well as on the morning of the first light session (screen #4). The participants had to demonstrate a consistent SIGH-SAD score of 21 or greater over 2 wk to be eligible for participation. Women of childbearing potential who were pregnant, nursing, or intending to become pregnant were excluded. Patients were also excluded if they used drugs or had history of alcohol abuse in the past year, if they met SCID criteria for Bipolar I, Psychotic disorders, or cognitive disorders; if they reported past suicide attempts or active current suicidal ideation; or if they worked night shift. Other exclusion criteria were HIV infection, systemic lupus, myocardial infarction or stroke, advanced glaucoma, and self-report of sensitivity to bright light or vision problems that are uncorrectable by glasses (*e.g.,* if they answered negatively when queried as to whether they could distinguish colors or see stars at night). Treatment with antidepressants, mood stabilizers, or antipsychotic medications during the one month prior to screening, as well as use of narcotic pain medicine were also criteria for exclusion. After complete description of the study, participants’ understanding was evaluated using a research consent form booklet. Informed consent was obtained to show participants’ agreement and voluntary enrolment in the study.

***Light treatment***

Treatment was performed using the Apollo BriteLITE 6 (Apollo, American fork, Utah) whose name has since changed to Phillips BriteLITE 6. (Phillips HealthCare, Andover MA, product HF 3310 <http://www.usa.philips.com/c-p/HF3310_60/britelite-6-energy-light>) with dimensions of 7.1 x 11 x 17.4 in / 18 x 28 x 44 cm), and a peak wavelength of 545 nm.

The first light treatment session was conducted at the General Clinical Research Center of the University of Maryland, and including teaching and reviewing the light treatment procedures with participants and assessing response to the initial treatment. The intensity of 10000 lux was verified during the first session with a light meter and was obtained consistently from a distance of 33 cm from the center of the light box to the eyes. To maintain the correct distance from the light box to the eye level, a string measuring 34 cm was tied just above the light box. Participants were instructed to check their distance by straightening the string from the light box to a midpoint between their eyes, just above the nose.

Participants completed home-based daily bright light therapy for 6 wk, and treatment beginning at 10000 lux for 60 min upon awakening[19].

Previous studies have shown that light therapy is generally most effective when administered earlier in the day[19-21], as early morning treatment advances circadian rhythms, which are often phase delayed in SAD patients[20,21]. Participants were also instructed to use a timer on the light box to automatically shut off treatment after the recommended time interval.

The protocol allowed for flexible duration of light exposure with weekly adjustment. Weekly assessments were completed by phone with trained clinicians to assess mood symptoms, adherence to light, side effects, and measures related to hunger and food craving. We decided against a fixed-dose treatment instead preferring a flexible administration to maximize response and adherence in a clinically plausible context. Duration of light treatment was increased by fifteen minutes daily for participants who did not have at least a 30% reduction in SIGH-SAD score at the end of week one, a 50% reduction in SIGH-SAD score at the end of week two, or did not fulfill remission criteria (SIGH-SAD score < 8) at the end of week three. Conversely, duration of treatment was decreased by fifteen minutes daily for any report of a side effect of 4 or greater on a 7-point Likert scale. The management of patients who showed poor response or side effects was discussed by a junior clinician with a senior psychiatrist who was blinded to patients’ study groupings. The methodology used in our study was similar to a protocol used in recent clinical trials comparing light treatment to cognitive-behavioral therapy in patients with SAD[22].

***Measures***

Depression scores were assessed using two measures, one semi-structured interview, the Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH- SAD)[18], and a self report measure, the Beck Depression Inventory-Second Edition (BDI-II)[23]. The primary outcome measure was the SIGH-SAD remission and response status, as defined above.

***Adherence measurement***

Participants were asked to complete a daily log reporting on the time and duration of light treatment used that day. Adherence logs were collected weekly by members of the research team and recorded. Adherence was defined as number of days in which light treatment was used as prescribed, and non-adherence defined as total number of days missed or not used as prescribed.

***Statistical methods***

Descriptive measures include means and standard deviations for continuous variables and proportions and percents for categorical variables. Comparisons of the participants by race were made using *t*-tests for continuous variables (change from baseline for mood measures and adherence), and Chi-square tests for categorical variables. Multiple linear regression analysis was used to compare race sub-groups on changes in depression scores with adjustment for adherence, age, education, and gender. A sensitivity analysis for remission was performed including all participants who entered the study rather than just those who completed it. Four participants who did not receive treatment were also included. Assumptions for the sensitivity analysis were that: (1) If SIGH-SAD was ≤ 8 (*i.e.,* remission) at week 6, then patient was considered in remission at the end of the study; (2) If SIGH-SAD data were missing at week 6, but the rating at week 4 was ≤ 8, then patient was considered in remission at the end of the study; and (3) If data for both weeks 4 and 6 were missing, then patients were considered not in remission. For the sensitivity analysis of adherence, all patients were included. If data for one week were missing, we counted that as 7 d missed.

**RESULTS**

No differences were found between African Americans and Caucasians in mean age, gender, marital status, or proportion of bipolar II patients. The overall educational level was lower in African Americans than Caucasians; specifically, a higher percentage of African Americans had a high school education or less (52% African Americans *vs* 26 % Caucasians, *P* = 0.03) as shown in Table 1.

In Table 2 we present a comparison between the two racial groups on pre-treatment and post-treatment depression scores using SIGH-SAD and BDI-II. There was no statistical difference between average baseline and post-treatment depression scores between Caucasian and African American patients.

Table 3 presents main outcome measures following six weeks of light treatment. Although both race groups showed similar decreases in the SIGH-SAD and BDI-II scores and similar post-treatment response rates, the proportion of remissions at post-treatment was significantly higher in Caucasians than in African Americans (46% African Americans *vs* 75% Caucasians, *P* = 0.02). In a logistic regression model of remission at 6 wk adjusted for age, gender, education, and percent adherence, African Americans were less likely to achieve remission than Caucasians (OR = 0.25; 95%CI: 0.08, 0.81; *P* = 0.02). Table 3 also shows no group differences on adherence expressed as number of days missed or percent days adherence (equivalent measures). Adherence was 73% for African Americans and 82% for Caucasians.

After linear regression adjustment for age, gender, education, and adherence, there were no significant differences in treatment related changes in depression scores between African Americans and Caucasians. This is shown in Table 4.

Table 5 presents results of the intent-to-treat sample, including all those who were randomized. Based on the assumptions described in the Methods (see sensitivity analysis) for *n* = 78, in the logistic regression model of remission at 6 weeks (adjusted for gender, percent adherence, and education) African-Americans were less likely to achieve remission than Caucasians (OR = 0.21, 95%CI: 0.07-0.66; *P* = 0.008). Those who were lost to follow up at 6 wk were compared with those with 6 wk data using *χ*2 and *t*-test analyses. No significant race group differences were found for gender (*P* = 0.36), age (*P* = 0.96), baseline SIGH-SAD (*P* = 0.68), and baseline BDI-II (*P* = 0.71). An ANCOVA model including race, gender, and age did not show significant difference between the groups in light exposure duration (F = 2.480; df = 1, 60; *P* = 0.12).

**DISCUSSION**

In this study, African American participants with Seasonal Affective Disorder had a lower remission rate than Caucasian participants following six weeks of light treatment, but there were no significant differences between the two race groups in adherence, average symptomatic improvement, and response rates.To our knowledge, this is the first study investigating differences between African Americans and Caucasians in response to light treatment in Seasonal Affective Disorder.

Racial differences for treatment response and remission have been previously reported with pharmacological treatment of non-seasonal depression. From the Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) trial, Lesser *et al*[24] reported that African Americans had lower remission rates on the 17-item Hamilton Rating Scale for Depression and the 16-item Quick Inventory of Depressive Symptomatology-Self Report (18.6% and 22% respectively) compared to whites (30.1% and 36.1%). However, there was no statistically significant difference between races after adjusting for baseline socioeconomic, clinical, and demographic differences. In their analysis of DNA samples from the STAR\*D trial, Binder et al. showed that a Single Nucleotide Polymorphism [single-nucleotide polymorphisms (SNP); rs 10473984] variation within the corticotrophin-releasing hormone binding protein locus appeared contributory to poor response and lower remission to treatment with citalopram in African Americans and Hispanic patients[25]. In an earlier report from the STAR\*D trial, McMahon *et al*[26] reported that the A allele of the SNP marker HTR2A which encodes for serotonin 2A receptor was over six times more frequent in white than in black participants and was responsible for better response to citalopram by white participants compared to blacks. There are several factors that may explain why certain outcomes such as adherence and response rates were similar in African Americans and Caucasians in our study in contrast to significant racial differences reported in previous pharmacological trials. African Americans may perceive light therapy as more acceptable and less stigmatizing than medications. This hypothesis was not formally tested.

In general, the response rate of 81% and remission rate of 52% reported in this study are somewhat more favorable compared to other studies on light treatment for SAD[3,20,21,27]. For instance, Lam *et al*[28] compared light treatment using 10000 lux bright light for 30 min daily with fluoxetine 20 mg orally daily for 8 wk. Their study showed no significant difference in clinical response rate, which was 67% for both groups, while remission rates were 50% for light therapy and 54% for fluoxetine.

We also note that there was no significant difference in adherence to daily light treatment between African Americans and their Caucasian counterparts in our study. The adherence of 73% in African Americans and 82% in Caucasians in our study is similar to the 83.3% found by Michalak *et al*[29], and it compares favorably with adherence to antidepressants[30]. When compared to antidepressants, light treatment has more benign side effects[28], potentially leading to higher adherence. Other side effects, such as precipitating hypomania and mania, are similar in light treatment and antidepressants[31].Additionally, more rapid improvement with light treatment[28,32] may contribute to a better adherence with this non-pharmacological treatment.

The previously reported higher melanin content of the pupil and retinal pigment epithelium in African-Americans[33,34] may reduce the retinal illuminance in African-American SAD patients during light treatment. However, the magnitude of this effect is unclear, as is the effect of these reduced levels on remission.

***Study limitations***

Limitations of this study include open label design, a limited sample size, and absence of objective markers of adherence. The recruitment method may have induced a selection bias that may have influenced favorably, but spuriously, the adherence rate.

We also, did not collect information on number of lifetime depressive episodes or duration of current episode. The flexible dosing of treatment in our study, although representative of real world clinical practice, may have affected the outcomes. In addition, our generalizability may be limited as our inclusion and exclusion criteria may have led to selectively including a less severe subset of patients, having excluded patients with history of suicide attempts, current suicidal ideation, Bipolar 1 disorder, and comorbid substance abuse as well as patients on often used psychotropic medications. Including patients on psychotropic medications in the study, although increasing its generalizability, would have required unaffordably larger sample size and budget, to permit appropriate statistical adjustments.

This is the first study directly comparing light treatment outcome in two groups, African American and Caucasian patients. A similar average degree of symptomatic improvement and adherence in African Americans, combined with a previously reported lower awareness of Seasonal Affective Disorder in this minority group[8] justify increasing psychoeducation outreach efforts regarding Seasonal Affective Disorder and light treatment in that sub-sample of the population. However, there is a need to better understand the lower remission rate in African Americans, similar to that of antidepressant medications. In the subset of patients who do not achieve remission with light treatment, augmentation with antidepressant medication or cognitive behavioral therapy is currently advocated. Considering differences in pupil and retinal pigmentation in African Americans it might be possible that specific protocols with distinct light intensity and wavelength could reduce the reported racial remission gap. This is particularly important, as complete remission with antidepressant treatment is the target for all treatment modalities for mood disorders, considering implications for health, functioning, and quality of life.

**COMMENTS**

***Background***

Previous research studies have shown that Seasonal Affective Disorder prevalence in African Americans was similar to that of the general population living at similar altitude and whereas awareness of the disorder and its treatment was low among African Americans. Our study is the first look at this area of light treatment. We set out to bridge information gap as to whether African Americans would adhere and respond to treatment, or show remission of symptoms in a similar fashion as Caucasians if exposed to similar treatment for Seasonal Affective disorder. According to the authors of our study, the outcome of our research will then determine if and whether there is need to increase awareness of the disorder in the African American community.

***Research frontiers***

Research in this area is rapidly moving towards identification of biological markers of response to light therapy as well as individualization of treatment.

***Innovations and breakthrough***

Manufacturers of light boxes are now making dawn simulator light boxes which were shown in some previous studies to be superior in delivering full spectrum light in treatment of Seasonal Affective Disorder. Other studies have also shown that dawn simulation could be more efficacious in the treatment of Seasonal Affective Disorder compared to treatment using full spectrum light box. The author of the seminal paper in this research area has recently suggested that more than 10000 lux of light appears to be better in treating Seasonal Affective Disorder, although no research study has been done to test this hypothesis.

***Applications***

Seasonal Affective Disorder could be disabling for certain subset of afflicted patients. This modality of treatment used in this research is very attractive, especially to patients concerned about the side effects of antidepressant medications. Furthermore, for patients who require augmentation with antidepressants, the dose of medication could be kept low and thus minimize side effects.

***Terminology***

Seasonal Affective Disorder refers to types of mood disorders occurring during certain seasons and remitting with change of season. The most common pattern is depression in winter that remits in spring; African American refers to any person born in the United States of America and whose ancestors were of African extraction; Caucasian refers to any person born in the United States of American and whose ancestors were of European extraction; Depression refers to a state of lowered mood often accompanied by disturbances of sleep, energy, appetite, concentration, interests, and sexual drive; Response refers to decrease in symptoms by 50% on a measurement scale like the Hamilton scale for depression also called HAM-D; Remission refers to decrease in symptoms by up to 75 % on a measurement scale like the HAM-D.

***Peer review***

Our manuscript has been peer-reviewed by reviewers of Baishideng Publishing Group and received favorable reviews from all the reviewers. We have addressed all criticisms and concerns of the reviewers.

**ACKNOWLEDGEMENTS**

The authors thank Monika Acharya, MD, Muhammad Tariq, MD, Humaira Siddiqi, MD, and Partam Manalai, MD for their help in screening and rating patients. The authors declare no conflict of interest within the past 5 years.

**REFERENCES**

1 **Rosenthal NE**, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, Mueller PS, Newsome DA, Wehr TA. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. *Arch Gen Psychiatry* 1984; **41**: 72-80 [PMID: 6581756 DOI: 10.1001/archpsyc.1984.01790120076010]

2 **Terman JS**, Terman M, Schlager D, Rafferty B, Rosofsky M, Link MJ, Gallin PF, Quitkin FM. Efficacy of brief, intense light exposure for treatment of winter depression. *Psychopharmacol Bull* 1990; **26**: 3-11 [PMID: 2371371]

3 **Eastman CI**, Young MA, Fogg LF, Liu L, Meaden PM. Bright light treatment of winter depression: a placebo-controlled trial. *Arch Gen Psychiatry* 1998; **55**: 883-889 [PMID: 9783558 DOI: 10.1001/archpsyc.55.10.883]

4 **Golden RN**, Gaynes BN, Ekstrom RD, Hamer RM, Jacobsen FM, Suppes T, Wisner KL, Nemeroff CB. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. *Am J Psychiatry* 2005; **162**: 656-662 [PMID: 15800134 DOI: 10.1176/appi.ajp.162.4.656]

5 **Lieverse R**, Van Someren EJ, Nielen MM, Uitdehaag BM, Smit JH, Hoogendijk WJ. Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial. *Arch Gen Psychiatry* 2011; **68**: 61-70 [PMID: 21199966 DOI: 10.1001/archgenpsychiatry.2010.183]

6 **Neumeister A**, Turner EH, Matthews JR, Postolache TT, Barnett RL, Rauh M, Vetticad RG, Kasper S, Rosenthal NE. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. *Arch Gen Psychiatry* 1998; **55**: 524-530 [PMID: 9633671 DOI: 10.1001/archpsyc.55.6.524]

7 **Wirz-Justice A**. From the basic neuroscience of circadian clock function to light therapy for depression: on the emergence of chronotherapeutics. *J Affect Disord* 2009; **116**: 159-160 [PMID: 19446885 DOI: 10.1016/j.jad.2009.04.024]

8 **Agumadu CO**, Yousufi SM, Malik IS, Nguyen MC, Jackson MA, Soleymani K, Thrower CM, Peterman MJ, Walters GW, Niemtzoff MJ, Bartko JJ, Postolache TT. Seasonal variation in mood in African American college students in the Washington, D.C., metropolitan area. *Am J Psychiatry* 2004; **161**: 1084-1089 [PMID: 15169697 DOI: 10.1176/appi.ajp.161.6.1084]

9 **Melfi CA**, Croghan TW, Hanna MP, Robinson RL. Racial variation in antidepressant treatment in a Medicaid population. *J Clin Psychiatry* 2000; **61**: 16-21 [PMID: 10695640 DOI: 10.4088/JCP.v61n0105]

10 **Bogner HR**, Lin JY, Morales KH. Patterns of early adherence to the antidepressant citalopram among older primary care patients: the prospect study. *Int J Psychiatry Med* 2006; **36**: 103-119 [PMID: 16927582 DOI: 10.2190/DJH3-Y4R0-R3KG-JYCC]

11 **Bulatao RA,** Anderson NB, editors. Understanding Racial and Ethnic Differences in Health in Late Life: A Research Agenda. Washington: National Academies Press, 2004: 9

12 **Rosenthal NE,** Genhart MJ, Sack DA, Skwerer RJ, Wehr TA. Seasonal affective disorder and its relevance for the understanding and treatment of bulimia. In: Hudson JI, Pope HG, editors. The Psychobiology of Bulimia. Washington: American Psychiatric Press, 1987: 205-228

13 **Magnusson A**. An overview of epidemiological studies on seasonal affective disorder. *Acta Psychiatr Scand* 2000; **101**: 176-184 [PMID: 10721866 DOI: 10.1034/j.1600-0447.2000.101003176.x]

14 **Mersch PP**, Vastenburg NC, Meesters Y, Bouhuys AL, Beersma DG, van den Hoofdakker RH, den Boer JA. The reliability and validity of the Seasonal Pattern Assessment Questionnaire: a comparison between patient groups. *J Affect Disord* 2004; **80**: 209-219 [PMID: 15207934 DOI: 10.1016/S0165-0327(03)00114-9]

15 **Magnusson A**. Validation of the Seasonal Pattern Assessment Questionnaire (SPAQ). *J Affect Disord* 1996; **40**: 121-129 [PMID: 8897111 DOI: 10.1016/0165-0327(96)00036-5]

16 **Young MA**, Blodgett C, Reardon A. Measuring seasonality: psychometric properties of the Seasonal Pattern Assessment Questionnaire and the Inventory for Seasonal Variation. *Psychiatry Res* 2003; **117**: 75-83 [PMID: 12581822 DOI: 10.1016/S0165-1781(02)00299-8]

17 **First MB,** Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM–IV Axis I Disorders (SCID—Clinician Version). New York: New York State Psychiatric Institute Biometrics Research Department, 1997

18 **Williams JBW,** Link MJ, Rosenthal NE, Amira L, Terman M. Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorders Version (SIGH SAD), revised ed. New York: New York State Psychiatr Inst, 2002

19 **Levitan RD**. What is the optimal implementation of bright light therapy for seasonal affective disorder (SAD)? *J Psychiatry Neurosci* 2005; **30**: 72 [PMID: 15645001]

20 **Terman M**, Terman JS, Quitkin FM, McGrath PJ, Stewart JW, Rafferty B. Light therapy for seasonal affective disorder. A review of efficacy. *Neuropsychopharmacology* 1989; **2**: 1-22 [PMID: 2679625 DOI: 10.1016/0893-133X(89)90002-X]

21 **Terman JS**, Terman M, Lo ES, Cooper TB. Circadian time of morning light administration and therapeutic response in winter depression. *Arch Gen Psychiatry* 2001; **58**: 69-75 [PMID: 11146760 DOI: 10.1001/archpsyc.58.1.69]

22 **Rohan KJ**, Roecklein KA, Tierney Lindsey K, Johnson LG, Lippy RD, Lacy TJ, Barton FB. A randomized controlled trial of cognitive-behavioral therapy, light therapy, and their combination for seasonal affective disorder. *J Consult Clin Psychol* 2007; **75**: 489-500 [PMID: 17563165 DOI: 10.1037/0022-006X.75.3.489]

23 **Beck AT**, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. *J Pers Assess* 1996; **67**: 588-597 [PMID: 8991972 DOI: 10.1207/s15327752jpa6703\_13]

24 **Lesser IM**, Castro DB, Gaynes BN, Gonzalez J, Rush AJ, Alpert JE, Trivedi M, Luther JF, Wisniewski SR. Ethnicity/race and outcome in the treatment of depression: results from STAR\*D. *Med Care* 2007; **45**: 1043-1051 [PMID: 18049344 DOI: 10.1097/MLR.0b013e3181271462]

25 **Binder EB**, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, Fava M, Bradley B, Ressler KJ, Nemeroff CB. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. *Arch Gen Psychiatry* 2010; **67**: 369-379 [PMID: 20368512 DOI: 10.1001/archgenpsychiatry.2010.18]

26 **McMahon FJ**, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. *Am J Hum Genet* 2006; **78**: 804-814 [PMID: 16642436 DOI: 10.1086/503820]

27 **Terman M**, Terman JS. Controlled trial of naturalistic dawn simulation and negative air ionization for seasonal affective disorder. *Am J Psychiatry* 2006; **163**: 2126-2133 [PMID: 17151164 DOI: 10.1176/appi.ajp.163.12.2126]

28 **Lam RW**, Levitt AJ, Levitan RD, Enns MW, Morehouse R, Michalak EE, Tam EM. The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. *Am J Psychiatry* 2006; **163**: 805-812 [PMID: 16648320 DOI: 10.1176/appi.ajp.163.5.805]

29 **Michalak EE**, Murray G, Wilkinson C, Dowrick C, Lam RW. A pilot study of adherence with light treatment for seasonal affective disorder. *Psychiatry Res* 2007; **149**: 315-320 [PMID: 17161464 DOI: 10.1016/j.psychres.2006.05.005]

30 **Lee MS**, Lee HY, Kang SG, Yang J, Ahn H, Rhee M, Ko YH, Joe SH, Jung IK, Kim SH. Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders. *J Affect Disord* 2010; **123**: 216-221 [PMID: 19914719 DOI: 10.1016/j.jad.2009.10.002]

31 **Sohn CH**, Lam RW. Treatment of seasonal affective disorder: unipolar versus bipolar differences. *Curr Psychiatry Rep* 2004; **6**: 478-485 [PMID: 15538998 DOI: 10.1007/s11920-004-0014-z]

32 **Virk G,** Reeves G, Rosenthal NE, Sher L, Postolache TT. Short exposure to light treatment improves depression scores in patients with seasonal affective disorder: A brief report. *Int J Disabil Hum Dev* 2009; **8**: 283-286 [PMID: 20686638 DOI: 10.1901/jaba.2009.8-283]


33 **van den Berg TJ**, IJspeert JK, de Waard PW. Dependence of intraocular straylight on pigmentation and light transmission through the ocular wall. *Vision Res* 1991; **31**: 1361-1367 [PMID: 1891824 DOI: 10.1016/0042-6989(91)90057-C]

34 **Kardon RH**, Hong S, Kawasaki A. Entrance pupil size predicts retinal illumination in darkly pigmented eyes, but not lightly pigmented eyes. *Invest Ophthalmol Vis Sci* 2013; **54**: 5559-5567 [PMID: 23882686 DOI: 10.1167/iovs.13-12319]

**P-Reviewer:** Chakrabarti S, Tampi RR **S-Editor:** Tian YL

**L-Editor: E-Editor:**

**Figure 1 Flow chart showing number of participants from beginning to end of study.** SPAQ: Seasonal pattern assessment questionnaire; N: Total population sample at beginning of study; *n*: Population sample at various stages after initial screening; SCID-IV: Structured Clinical Interview for DSM-IV; SAD: Seasonal Affective Disorder; SIGH-SAD: Structured Interview Guide for the Hamilton rating scale-Seasonal Affective Disorder subscale.



**Figure 2 Graph comparing remission scores between the two groups.** SIGH-SAD: Structured Interview Guide for the Hamilton rating scale - Seasonal Affective Disorder subscale.

**Table 1 Characteristics of the participants in the two groups *n* (%)**

**African Americans Caucasians**

**Variable (*n* = 51) (*n* = 27) *P*-value1**

Age, yr, mean ± SD 43.1 (10.3) 47.0 (10.1) 0.11

Gender male 19 (37.3) 14 (51.9) 0.21

Bipolar II Diagnosis 2 (3.9) 1 (3.7) 0.96

Education

High school or less 26 (52.0) 7 (25.9) 0.03

Marital status

Married or cohabiting 7 (14.0) 5 (18.5) 0.42

Widowed, divorced

or separated 12 (24.0) 11 (40.8)

Never married 31 (62.0) 11 (40.7)

1*P*-values from *t*-test comparing races on age; *χ*2 for other variables.

**Table 2 Comparison of pretreatment and post-treatment depression scores**

**African Americans Caucasians**

**Variable (*n* = 51) (*n* = 27) *P*-value1**

**Pre-treatment mood scores**

SIGH-SAD

Mean ± SD 33 (6.9) 31 (6.4) 0.22

BDI-II

Mean ± SD 25 (10.9) 23.6 (8.4) 0.58

**Post-treatment mood scores** (*n* = 41)(*n* = 24)

SIGH-SAD

Mean ± SD 9.31 (6.9) 6.79 (6.0) 0.15

BDI-II

Mean ± SD 9 (7.9) 7.3 (7.4) 0.41

1*P*-values from *t*-test compare pre-treatment and post-treatment mood scores on key depression measures. SIGH-SAD: Structured Interview Guide for Hamilton-Seasonal Affective Disorder subscale; BDI-II: Beck Depression Inventory Second Edition.

**Table 3 Response, remission, and depression score changes by groups**

**African Americans Caucasians Variable (*n* = 41) (*n* = 24) *P*-value**

Response, 50% reduction SIGH-SAD

*n* (%) 33 (80.5) 20 (83.3) 0.78

Remission, SIGH-SAD < 8

*n* (%) 19 (46.3) 18(75.0) 0.02

SIGH-SAD, % change

Mean ± SD -70.4 (22.7) -76.0 (22.6) 0.34

BDI-II, % change

Mean ± SD -61.8 (32.2) -68.1 (32.9) 0.46

POMS-A, % change

Mean ± SD -46.6 (46.7) -46.8 (48.8) 0.98

POMS-D, % change

Mean ± SD -52.7 (47.1) -49.2(54.9) 0.78

Treatment days missed

Mean ± SD 8.7(11.0) 7.4(8.3) 0.61

Percent Adherence

Mean ± SD 79.4 (26.2) 82.4(19.7) 0.61

SIGH-SAD: Structured Interview Guide for Hamilton-Seasonal Affective Disorder subscale; BDI-II: Beck Depression Inventory Second Edition; POMS-A: Profile of Mood States-Anxiety; POMS-D: Profile of Mood States-Depression.

**Table 4 Adjusted mean changes in depression score outcomes in African Americans & Caucasians, adjusted for adherence, age, education and gender**

**African Americans Caucasians Variable (*n* = 41) (*n* = 24) *P*-value**

Mood scale

SIGH-SAD -22.9 (1.6) -25.2 (2.1) 0.41

BDI-II -16.6 (2.0) -16.4 (2.6) 0.95

SIGH-SAD: Structured Interview Guide for Hamilton-Seasonal Affective Disorder subscale; BDI-II: Beck Depression Inventory Second Edition.

**Table 5 Sensitivity analysis including all participants *n* (%)**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**African-Americans Caucasians *P*-value**

**(*n* = 51) (*n* = 27)**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Remission, SIGH-SAD ≤ 8 at 4 or 6 wk:

*n* (%) 19 (37.3) 18 (66.7) 0.01

Treatment days missed

Mean ± SD 11.3 (13.9) 7.4(8.3) 0.13

Percent Adherence

Mean ± SD 73.2 (33.1) 82.4(19.7) 0.13

SIGH-SAD: Structured interview guide for the Hamilton-Seasonal Affective Disorder subscale.